Moderna says Europe-bound COVID-19 vaccine deliveries are on track
Reuters
Published Apr 07, 2021 05:28AM ET
Updated Apr 07, 2021 06:45AM ET
By John Miller
ZURICH (Reuters) -Deliveries of Moderna (NASDAQ:MRNA)'s COVID-19 vaccine are on track to meet the number of doses it promised to the European Union, a spokesperson for the U.S.-based drugmaker said on Wednesday, following a report of delays in Germany.
"Moderna is committed to meeting all quarterly contractual delivery agreements with the European Commission and individual Member States," the spokesperson said in an email to Reuters.
"April deliveries are on track to meet the dose ranges previously communicated to governments."
A German language publication of Business Insider had reported that the delivery of up to 878,400 doses of Moderna's vaccine due from April 26 to May 2 might not take place, citing unidentified sources within the German health ministry.
In response to questions about any interruptions, Moderna said that it "does not cancel delivery shipments, but can at times provide updates (on) delivery guidance based on the trajectory of manufacturing and batch release".
The German health ministry said that Moderna had not communicated any changes to its delivery plan.
Moderna declined to release specifics about the monthly dose range bound for Europe, though it previously has confirmed 2021 deliveries would include 160 million doses for the EU and 17 million doses for Britain. Worldwide, it has committed to producing at least 700 million doses this year.
Concerns over vaccine availability in Germany and the rest of the European Union remain high after the initial phase of the bloc's rollout significantly trailed vaccination rates in Britain and the United States and as variants spread, increasing urgency to get more shots into peoples' arms.
Ingredients for the company's COVID-19 vaccine destined for Europe, Canada, Japan, Korea and other countries outside the United States are made at Lonza facilities in Switzerland, before being packaged into vials at separate locations in Spain and France.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.